Pharmaceutical

As its lead candidate advances into a late-stage trial for pulmonary arterial hypertension, Inhibikase Therapeutics has picked up a commercial leader...

The nation's largest pediatrician professional organization urged providers and insurers to consider its evidence-backed vaccine recommendations, as o...

With sales of atopic dermatitis treatment Adbry scaling up in the U.S., Leo Pharma is accomplishing one of the goals established by CEO Christophe Bou...

Several U.S. pharma companies that had posted revenue declines in the first quarter bounced back in the second quarter, including Pfizer, Regeneron an...

With three new antibiotics set to shake up the stagnant treatment landscape for uncomplicated urinary tract infections in the U.S., Dublin-based Iteru...

The FDA said data for PTC's drug did not prove "substantial evidence of efficacy." Elsewhere, the FDA delayed its decision on a Regenxbio gene therapy...

On an earnings call, CSL CEO Paul McKenzie described weakness in the U.S. market for seasonal flu vaccines as “disappointing” and “highly irrational.”

The company’s market value was nearly cut in half following trial results showing higher rates of treatment discontinuations among people receiving Vi...

The FDA has signed off on an accelerated approval for Novo Nordisk's Wegovy to treat certain adults with metabolic-associated steatohepatitis. The gre...

Earlier this summer, HHS Secretary Robert F. Kennedy ousted all members of the CDC's vaccine advisory committee in an effort to remove industry influe...